Stellar Biotechnologies (SBOT) Receives Coverage Optimism Score of 0.04
News headlines about Stellar Biotechnologies (NASDAQ:SBOT) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.5174022548273 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Shares Seesawing on Volume: Stellar Biotechnologies Inc (SBOT) (wisdomsave.com)
- Stellar Biotechnologies, Inc. (SBOT) Releases Quarterly Earnings Results, Hits Estimates (americanbankingnews.com)
- Investors Are Circling Stellar Biotechnologies Inc (SBOT), What Do the Numbers Tell Us? – Evergreen Caller (evergreencaller.com)
- Stellar Biotechnologies Reports Third Quarter 2017 Financial Results – Markets Insider (markets.businessinsider.com)
- Stellar Biotechnologies Reports Third Quarter 2017 Financial Results – PR Newswire (press release) (prnewswire.com)
Shares of Stellar Biotechnologies (SBOT) opened at 1.22 on Tuesday. The stock’s 50 day moving average price is $1.31 and its 200-day moving average price is $1.43. Stellar Biotechnologies has a 1-year low of $1.05 and a 1-year high of $3.00. The company’s market capitalization is $12.83 million.
Stellar Biotechnologies (NASDAQ:SBOT) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.34 million. On average, equities analysts predict that Stellar Biotechnologies will post ($0.47) EPS for the current year.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.